相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.
J. Delord et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)
Kim A. Margolin et al.
CLINICAL CANCER RESEARCH (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
F. Xing et al.
ONCOGENE (2012)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
J. Lin et al.
BRITISH JOURNAL OF CANCER (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436)
K. L. Nathanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
KRAS and BRAF: drug targets and predictive biomarkers
Efsevia Vakiani et al.
JOURNAL OF PATHOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma
Amelie Marquette et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
F. M. Kaplan et al.
ONCOGENE (2011)
Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
Elisabetta Vergani et al.
NEOPLASIA (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
Begona Comin-Anduix et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2010)
Unusual Presentation of Large-Cell Poorly Differentiated Neuroendocrine Carcinoma of the Epiglottis
Kevin J. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212
J. R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
c-Kit mutants require hypoxia-inducible factor 1α to transform melanocytes
G. Monsel et al.
ONCOGENE (2010)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
William D. Tap et al.
NEOPLASIA (2010)
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Nathalie Dhomen et al.
CANCER CELL (2009)
Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma
Matthew W. VanBrocklin et al.
CANCER RESEARCH (2009)
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
Ravi K. Amaravadi et al.
CLINICAL CANCER RESEARCH (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation
Bin Zheng et al.
MOLECULAR CELL (2009)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis
Yanhua Zhao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2008)
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
Mark S. Cragg et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Mutant B-RAF mediates resistance to anoikis via Bad and Bim
K. Boisvert-Adamo et al.
ONCOGENE (2008)
Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
Robert A. Cartlidge et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
B- and C-RAF display essential differences in their binding to Ras - The isotype-specific N terminus of B-RAF facilitates ras binding
Andreas Fischer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Oncogenic BRAF regulates β-Trcp expression and NF-κB activity in human melanoma cells
J. Liu et al.
ONCOGENE (2007)
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing bak activation and bax translocation
Shuang Chen et al.
CANCER RESEARCH (2007)
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species
Monique Verhaegen et al.
CANCER RESEARCH (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
Nicolas Dumaz et al.
CANCER RESEARCH (2006)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen et al.
BRITISH JOURNAL OF CANCER (2006)
The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf
Kenta Terai et al.
EMBO JOURNAL (2006)
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
E Wardelmann et al.
CLINICAL CANCER RESEARCH (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
MJ Garnett et al.
MOLECULAR CELL (2005)
Raf: A strategic target for therapeutic development against cancer
M Beeram et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Role of epidermal growth factor receptor signaling in RAS-driven melanoma
N Bardeesy et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms
NH Tran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Mutant V599EB-RAF regulates growth and vascular development of malignant melanoma tumors
A Sharma et al.
CANCER RESEARCH (2005)
Regulation of Raf through phosphorylation and N terminus-C terminus interaction
HR Chong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
S Roumiantsev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to ST157, and they can pre-exist to the onset of treatment
C Roche-Lestienne et al.
BLOOD (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase
KA Furge et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism
J Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation
B Baumann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
